Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cyclosporine/Methotrexate vs Cyclosporine/T-Cell Depletion for GVHD Prophylaxis
NCT00003056Phase 3Terminated
- Sponsor
- Takeda
- Start
- Apr 1997
- Primary completion
- Jun 2003
- Modality
- Stem Cell Therapies
- Countries
- 2
01
Overview
A Phase 3 trial of CD34+ hematopoietic progenitor cells in graft-versus-host disease (GVHD), sponsored by Takeda. Started Apr 1997; status: terminated.
02
Drugs
CD34+ hematopoietic progenitor cells
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT00003056.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00003056.